Sofinnova
Maha Katabi, PhD, CFA

Maha Katabi, PhD, CFA

General Partner

Maha Katabi is an experienced investor with over two decades in managing public and private biotech companies through bull and bear markets. She is focused on investing in development stage biopharmaceuticals and is currently a member of the board of directors of Aerovate, Gyroscope, Northsea, Quanta and Vera.

Prior to joining Sofinnova in 2019, Maha co-invested with our team in multiple companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (TSRX-acquired by Cubist). She was a partner and portfolio manager at Sectoral where she formed and led a dedicated investment team and advisory board to drive investments in private companies and was a Portfolio Manager for a family of funds invested in small cap healthcare companies. She led the firm’s investments in 12 private biotech companies, 2 of which were acquired and 8 of which went public, with 5 trading at valuations greater than $1B.

Prior to Sectoral, Maha was Vice-President at Ventures West Management since 2004, a venture capital firm focusing on technology and life sciences investments in North America. She started her venture capital career in 1999 at T2C2 Capital Bio, a seed fund focused on university start-ups.

Maha received her BSc In Biology and PhD in Pharmacology from McGill University, where she was a Cancer Research Society fellow, and is a CFA charterholder since 2011. She currently serves as Chair of the board of Exactis Innovation, a not-for profit oncology precision medicine network and has served on the Canadian Task Force for COVID-19 Therapeutics until February 2021.

Active Companies

Alumni Companies